Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2023-04-25 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
中泰证券股份有限公司关于对北京诺思兰德生物技术股份有限公司公司治理的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report by Zhongtai Securities Co., Ltd. as the sponsor institution for Beijing Nuosiland Biotechnology Co., Ltd., concerning the company's 2022 annual corporate governance special self-inspection and regulatory activities. It includes comprehensive information on corporate governance, internal systems, board and management structure, decision-making procedures, governance constraints, and compliance with laws and regulations. The document is titled as a "special inspection report" on corporate governance for the year 2022, indicating it is a standalone audit or inspection report rather than a full annual report or other filing types. It does not present full financial statements or quarterly results, nor is it a brief announcement or a presentation. The content aligns with the definition of an Audit Report / Information (AR) as it covers applied governance principles, compliance, and internal control assessments. The document length (5396 characters) supports it being a substantive report rather than a short announcement. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2022
2023-04-25 Chinese
独立董事候选人声明（徐辉）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate, Xu Hui, for Beijing Northland Biotechnology Co., Ltd. It details the candidate's qualifications, independence, and compliance with relevant laws and regulations for serving as an independent director. There are no financial statements, earnings data, or report summaries present. The document is a regulatory announcement related to board/management information, specifically about a director candidate's declaration. It is not an annual report, audit report, earnings release, or any financial report. It fits best under Board/Management Information (MANG) as it concerns board membership and director qualifications.
2023-04-25 Chinese
关于 2023 年度公司董事、监事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the remuneration scheme for the company's directors, supervisors, and senior management personnel for the year 2023. It details the salary standards and approval procedures, including the independent directors' opinions and the board meeting dates. There is no financial data or report content, but rather a disclosure about compensation plans. This fits the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2023-04-25 Chinese
独立董事候选人声明（任自力）
Board/Management Information Classification · 95% confidence The document is a statement by an independent director candidate confirming qualifications and independence according to regulatory requirements. It includes legal references and compliance affirmations but does not contain financial data, financial results, or report content. It is a regulatory announcement related to board/management information, specifically about a director candidate's declaration. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on director nomination and qualifications, not a full report or announcement of voting results.
2023-04-25 Chinese
关于NL005项目IIb期临床试验完成全部受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of patient enrollment in a Phase IIb clinical trial for a drug candidate. It includes details about the clinical trial design, the drug's biological function, patent status, and potential impact on the company's financials. The document is short (1195 characters) and serves as an update on a research project milestone rather than a financial report or regulatory filing. It does not contain financial statements, audit information, or management changes. It is not a report publication announcement since it provides substantive information about the clinical trial progress. The content fits best under a general regulatory announcement category as it informs investors about a significant development but does not fall into more specific categories like earnings release or management reports.
2023-02-28 Chinese
2022年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a 2022 annual performance forecast announcement from Beijing Northland Biotech Co., Ltd. It contains preliminary financial data for the full year 2022 but explicitly states that the data is unaudited and subject to change in the final annual report. The document is short (718 characters) and serves as a forward-looking earnings preview rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis, only a forecast and risk warning. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of periodic financial results or forecasts. FY 2022
2023-02-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.